Investigating how certain immune cells respond to cancer
Official title: Tissue-Resident Adaptive CD56bright NK Cell Responses in Cancer
Funded at University of Minnesota · NIH-10996575 · Data updated 2026-11-12
This study is looking at special immune cells called natural killer (NK) cells to see how they help fight cancer, especially focusing on certain types that might be better at attacking tumors and bringing in other immune helpers, which could lead to better treatments for cancer patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $53,526 |
| NIH project number | 1F30CA294723-01 |
| Project ID | NIH-10996575 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who have a variety of tumor types and are interested in understanding how their immune response can be enhanced.
✕Less likely to help
Patients with non-cancerous conditions or those who do not have a significant immune response may not benefit from this research.
What this research studies
This research focuses on understanding the role of specific immune cells, known as natural killer (NK) cells, in fighting cancer. It examines different subtypes of NK cells, particularly those that reside in tissues and have memory-like properties, to see how they can effectively kill cancer cells and recruit other immune cells to the tumor site. By analyzing data from a large number of cancer patients, the researchers aim to identify which NK cell subtypes are most effective in anti-tumor responses. This could lead to new insights into enhancing cancer immunotherapy.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by harnessing the power of specific immune cells to better target and eliminate tumors.
How similar studies have gone: Other research has shown promising results in utilizing immune cells for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Lozada, John Roy — University of Minnesota
- Study coordinator: Lozada, John Roy
Related research
Other NIH-funded projects on the same topics.
-
Investigating biological markers related to human reproduction and development
This study is looking at how different factors in our bodies affect reproduction and the health of children and teens, and it's for anyone interested in understanding more about these important topics by analyzing samples like blood and urine without changing anything in their daily lives.
-
AI-powered liver cancer screening using ultrasound blood flow patterns
A new AI-based method analyzes liver blood flow signals to help detect liver cancer early in people with liver disease, especially in settings with limited resources.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Understanding how survivorship care plans affect health outcomes for cancer survivors
A study will look at whether survivorship care plans help reduce deaths and improve health for adults who have survived cancer.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Minnesota Population Center: a hub for migration, family and community data science
A university research center helps researchers study population dynamics by sharing data, training researchers, and communicating findings to diverse audiences.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.